Navigation Links
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Date:12/15/2007

hich is the absence of histological evidence of cancer cells in the tissue specimen, plus near pathological complete response, which is less than or equal to 5 millimeters of residual cancer). Additionally, HER2-negative patients experienced a clinical response rate of 76 percent and 15 percent pathological response with the combination of solely Xeloda and Taxotere. In patients with HER2-negative tumors, a decrease from 6.1 to 2.8 centimeters was observed; in HER2-positive patients, the reduction was from 5.6 to 1.6 centimeters.

"The XeNA results demonstrate the potential for oral Xeloda to serve as the cornerstone of combination chemotherapy in the treatment of early invasive breast cancer," said Lars Birgerson, M.D., PhD, Vice President of Global Head Medical Affairs at Roche.

Invasive breast cancer, also known as infiltrating breast cancer, is cancer that has spread to surrounding, healthy tissue. Most invasive breast cancers start in the ducts, but can spread to other parts of the body through the blood and lymph systems. Breast cancer is the most common cancer among women, other than skin cancer. It is the second leading cause of cancer death in women, after lung cancer. According to the American Cancer Society (ACS), about 178,480 women in the United States will be found to have invasive breast cancer in 2007 and about 40,460 women will die from the disease this year.

About the Study

This multi-center, open-label XeNA trial enrolled 157 (156 evaluable) patients with newly-diagnosed invasive breast cancer (planned sample size 122 HER2-negative; 34 HER2-positive) and was designed to investigate the activity of a short non-anthracycline-based preoperative treatment for early breast cancer. Efficacy results for 134 patients as well as toxicity data for the total evaluable population (156 patients) were included in this interim analysis. The primary endpoint was the rate of pathological complete response rate (pCR) plus near pCR in the
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS)
2. Promising drug combination may help those with ocular melanoma that has spread
3. Combination therapy reverses effects of portal hypertension in rats
4. Combination vaccines okay for infants, study shows
5. Antidepressants and painkillers - a dangerous combination
6. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
7. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
8. Drug combination might offer hope for patients deadly brain tumors
9. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
10. Combination targets: some drugs may work best when they work together
11. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... scheduled for October 27-29, 2015 in San Jose, CA. The first event ... focus on the void that exists where battery development and energy storage innovation ...
(Date:8/27/2015)... ... , ... In addition to its existing Doctor of Philosophy in Leadership and ... its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of ... nurses for the highest level of clinical nursing practice. , “Our vision is ...
(Date:8/27/2015)... ... ... North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open a free-standing ... located at US Highway 19 North and Highlands Boulevard, less than eight miles from the ... project is slated to begin in September 2015. , The new 24-bed facility ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
(Date:8/27/2015)... ... 27, 2015 , ... Z-Medica®, LLC, a leading developer and ... website http://www.Z-Medica.com , to further support the company’s corporate positioning. , The ... , “We launched a branded website last year to show our customers ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Z-Medica® Launches New Corporate Website 2
... England, both in terms of lives and money nearly ... report published today by the All Party Parliamentary Group (APPG) ... Lives - concludes that, despite effective treatments, there are 365 ... with unnecessary seizures, and 74,000 people are taking anti-epilepsy drugs ...
... tentative agreement with Delmont Laboratory to introduce its immunotherapeutic ... . According to this initial agreement, Delmont Laboratory will ... manufactures for the final packaging in China. ... agreement is to be signed. This product requires a ...
... data from its Phase IIb study in Alzheimer's disease (AD) ... and treated as diabetes of the brain. ... of amyloid beta plaques in the brain, yet recent research ... the brains of mice gives rise to some of the ...
... Diagnostics today announces that it has completed its ... with BioVeris for approximately $600 million on April ... Diagnostics now owns the patents for Electrochemiluminescence (ECL) ... the human diagnostics field into new market segments ...
... confirmed that the potentially lethal H5N1 strain of bird flu ... the country, the second such incident here in a week. ... the area around Frohburg, near Liepzig, second incidence of the ... ,The discovery followed the confirmation on Sunday of ...
... that air pollution affects women more than men . ... groups of mice with pneumonia. One group was exposed ... filtered air. ,The exposure to ozone significantly ... compared to males, reported science portal SCIENCE A GoGo. ...
Cached Medicine News:Health News:Blunders in Epilepsy Care Cost Lives, and Money UK Report 2Health News:Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain 2
(Date:8/27/2015)... LONGMONT, Colo. , Aug. 27, 2015 /PRNewswire/ ... focused on the development of Next Generation ... for applications in high speed fiber-optic data ... Michael Lebby has been appointed to ... Lebby,s reputation in the field of optoelectronics is ...
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Fibrosis Foundation (PFF) and Veracyte, Inc. ... organizations are partnering on a U.S. patient survey ... interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis ... survey will assess the steps and time required ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Md., Sept. 13, 2011 Sodexo, Inc., a leader ... with Healthsense, Inc.  As a part of the agreement, ... existing senior living client communities – expanding Sodexo,s current ... Life for all of the people and communities they ...
... University of Michigan Health System has selected a new system-wide ... medical to communications devices, wireless phones and pagers for its ... Hospital. "Moving from a facility where numerous beds ... where beds are now separated into multiple rooms, we anticipated ...
Cached Medicine Technology:Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3New Hospitals to Implement New Communications Technology 2
Inquire...
Inquire...
Inquire...
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
Medicine Products: